Show simple item record

dc.contributor.authorRibeiro, Gen
dc.contributor.authorWilkinson, Peter Men
dc.date.accessioned2011-03-03T14:46:33Z
dc.date.available2011-03-03T14:46:33Z
dc.date.issued1984-12
dc.identifier.citationA clinical assessment of loading dose tamoxifen for advanced breast carcinoma. 1984, 10 (4):363-7 Clin Oncolen
dc.identifier.issn0305-7399
dc.identifier.pmid6509818
dc.identifier.urihttp://hdl.handle.net/10541/123467
dc.description.abstractSeventy patients with advanced breast carcinoma were treated with a loading dose regimen of 160 mg Tamoxifen on day 1 followed by a maintenance dose of 20 mg daily from day 2 onwards. Compliance was 100% and only 3 patients developed mild side effects. In 27% regression of disease was observed within 1 month and in 57% within 2 months. This regimen is recommended for routine clinical use.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Receptorsen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBreast Neoplasms
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshReceptors, Estrogen
dc.subject.meshTamoxifen
dc.subject.meshTime Factors
dc.titleA clinical assessment of loading dose tamoxifen for advanced breast carcinoma.en
dc.typeArticleen
dc.identifier.journalClinical Oncologyen
html.description.abstractSeventy patients with advanced breast carcinoma were treated with a loading dose regimen of 160 mg Tamoxifen on day 1 followed by a maintenance dose of 20 mg daily from day 2 onwards. Compliance was 100% and only 3 patients developed mild side effects. In 27% regression of disease was observed within 1 month and in 57% within 2 months. This regimen is recommended for routine clinical use.


This item appears in the following Collection(s)

Show simple item record